Abstract 4139474: Safety of Sodium-Glucose Cotransporter-2 Inhibitors Peri-Percutaneous Coronary Intervention: A National Experience
Alaa Rahhal(Hamad Medical Corporation), Khaled Mohamed(Hamad Medical Corporation), Firas Hamsho(Hamad Medical Corporation), Sumaya Alyafei(Hamad Medical Corporation), Ahmed Mahfouz(Hamad Medical Corporation), Abdulrahman Arabi(Hamad Medical Corporation), Barakat Aladwan(Hamad Medical Corporation), Mohanad Shehadeh(Unity Health System), Yamane Chawa(Hamad Medical Corporation), Nawras Al-Tikrety(Hamad Medical Corporation), Mohamad Dulli(Hamad Medical Corporation), Sham AlKodmani(Hamad Medical Corporation), Dana Alomari(Hamad Medical Corporation), Noor Moustafa(Hamad Medical Corporation), Wael Hamam(Hamad Medical Corporation), Hashim Mohammad(Hamad Medical Corporation)
Cited by 0
Related Papers
Applications of Artificial Intelligence in Philadelphia-Negative Myeloproliferative Neoplasms
|Diagnostics|2023|15
The transforming mutation E17K/AKT1 is not a major event in B-cell-derived lymphoid leukaemias
|British Journal of Cancer|2008|13
<i>TBX5</i> variant with the novel phenotype of mixed‑type total anomalous pulmonary venous return in Holt‑Oram Syndrome and variable intrafamilial heart defects
|Molecular Medicine Reports|2022|7
Extending the spectrum of <i>CLRN1</i>‐ and <i>ABCA4</i>‐associated inherited retinal dystrophies caused by novel and recurrent variants using exome sequencing
|Molecular Genetics & Genomic Medicine|2020|5